JP2007527914A5 - - Google Patents

Download PDF

Info

Publication number
JP2007527914A5
JP2007527914A5 JP2007502989A JP2007502989A JP2007527914A5 JP 2007527914 A5 JP2007527914 A5 JP 2007527914A5 JP 2007502989 A JP2007502989 A JP 2007502989A JP 2007502989 A JP2007502989 A JP 2007502989A JP 2007527914 A5 JP2007527914 A5 JP 2007527914A5
Authority
JP
Japan
Prior art keywords
patient
administering
inhibiting
human
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007502989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527914A (ja
Filing date
Publication date
Priority claimed from US10/992,303 external-priority patent/US20050197336A1/en
Application filed filed Critical
Publication of JP2007527914A publication Critical patent/JP2007527914A/ja
Publication of JP2007527914A5 publication Critical patent/JP2007527914A5/ja
Withdrawn legal-status Critical Current

Links

JP2007502989A 2004-03-08 2005-03-08 ヒストン脱アセチル化酵素の阻害剤 Withdrawn JP2007527914A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55164404P 2004-03-08 2004-03-08
US10/992,303 US20050197336A1 (en) 2004-03-08 2004-11-17 Inhibitors of histone deacetylase
PCT/US2005/007906 WO2005086898A2 (en) 2004-03-08 2005-03-08 Inhibitors of histone deacetylase

Publications (2)

Publication Number Publication Date
JP2007527914A JP2007527914A (ja) 2007-10-04
JP2007527914A5 true JP2007527914A5 (https=) 2008-04-10

Family

ID=34915721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007502989A Withdrawn JP2007527914A (ja) 2004-03-08 2005-03-08 ヒストン脱アセチル化酵素の阻害剤

Country Status (6)

Country Link
US (2) US20050197336A1 (https=)
EP (1) EP1755601A4 (https=)
JP (1) JP2007527914A (https=)
AU (1) AU2005221134A1 (https=)
CA (1) CA2558243A1 (https=)
WO (1) WO2005086898A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475766C (en) * 2002-03-13 2012-06-05 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
HRP20040805A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Carbonylamino derivatives as novel inhibitors histone deacetylase
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
EA012451B1 (ru) 2004-03-11 2009-10-30 4Сц Аг Новые амидозамещённые гидрокси-6-фенилфенантридины
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7772245B2 (en) * 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
JP4058106B2 (ja) * 2005-02-18 2008-03-05 アストラゼネカ アクチボラグ 抗菌性のピペリジン誘導体
JP2008530193A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ 化合物
WO2006092608A1 (en) * 2005-03-04 2006-09-08 Astrazeneca Ab Tricyclic derivatives of azetidine and pyrrole with antibacterial activity
CN101171247A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
CN101137623B (zh) 2005-03-15 2013-03-27 奈科明有限责任公司 N-磺酰基吡咯及其作为组蛋白脱乙酰酶抑制剂的用途
ES2553178T3 (es) 2005-05-18 2015-12-04 Janssen Pharmaceutica N.V. Derivados sustituidos de aminopropenil piperidina o morfolina como nuevos inhibidores de histona deacetilasa
BRPI0616040A2 (pt) 2005-09-21 2011-06-07 Nycomed Gmbh cloridrato de sulfonilpirról como inibidor de histona desacetilases
SI1928872T1 (sl) 2005-09-21 2012-06-29 4Sc Ag Novi sulfonilpiroli kot inhibitorji HDAC
JP5070214B2 (ja) * 2005-10-27 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤としてのスクエア酸誘導体
WO2007082876A1 (en) * 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
EP1981875B1 (en) 2006-01-19 2014-04-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
DK1981871T3 (da) 2006-01-19 2012-02-13 Janssen Pharmaceutica Nv Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase
WO2007082874A1 (en) * 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CA2631876C (en) * 2006-01-19 2014-05-27 Janssen Pharmaceutica N.V. Aminophenyl derivatives as inhibitors of histone deacetylase
CA2641579A1 (en) 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
CN105481788A (zh) * 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CN101677977A (zh) * 2006-11-10 2010-03-24 欣达克斯制药公司 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009049018A1 (en) * 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
CN101918389A (zh) * 2007-11-02 2010-12-15 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009089598A2 (en) * 2008-01-18 2009-07-23 Katholieke Universiteit Leuven Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
WO2010141932A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
US8394858B2 (en) * 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
WO2011106627A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN103169720B (zh) * 2011-12-21 2016-12-07 张雅珍 蒽环类抗生素及其可药用盐在治疗视网膜静脉阻塞中的用途
ITRM20120405A1 (it) * 2012-08-09 2014-02-10 C N C C S Scarl Collezione Naziona Le Dei Compost Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
EP3769757A3 (en) * 2013-10-18 2021-10-06 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
CN111484469B (zh) * 2020-05-14 2022-07-05 遵义医科大学 吡喃亚基丙二腈类光敏剂先导化合物合成方法及其应用
KR102514860B1 (ko) * 2020-12-01 2023-03-29 한국과학기술연구원 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
WO2025085848A1 (en) * 2023-10-20 2025-04-24 Arrepath, Inc. Antibacterial compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US5925672A (en) * 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
EP1748046A3 (en) * 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US7314953B2 (en) * 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002340253C1 (en) * 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
SE520636C2 (sv) * 2001-11-12 2003-08-05 Stroemsholmen Ab Anordning vid en energiackumelerande kolv-cylinderdon
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
AU2003226014A1 (en) * 2002-03-28 2003-10-13 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
US20030206946A1 (en) * 2002-04-26 2003-11-06 Yih-Lin Chung Methods for therapy of connective tissue disease
WO2003099760A1 (en) * 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc. Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
SE0202157D0 (sv) * 2002-07-09 2002-07-09 Biovitrum Ab Methods for identification of compounds modulating insulin resistance
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
RU2324483C2 (ru) * 2002-11-12 2008-05-20 Алькон, Инк. Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
US20040140461A1 (en) * 2003-01-22 2004-07-22 Lappen Alan Rick Configurable fence and gate systems
US7381825B2 (en) * 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase

Similar Documents

Publication Publication Date Title
JP2007527914A5 (https=)
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
IL182020A0 (en) Pharmaceutical composition comprising diclofenac
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
IL208982B (en) A preparation containing baclofen or a salt, derivative or delayed release formulation thereof for use in the treatment of Alzheimer's disease
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
ATE517619T1 (de) Stabilisierte pharmazeutische zusammensetzung mit fesoterodin
EP2152237A4 (en) NEW PHARMACEUTICAL COMPOSITION
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
BRPI0810928A2 (pt) "composição farmacêutica"
NO20085420L (no) Farmasøytisk formulering med fenylefrin og preparater for absorpsjon i tykktarmen
EP2214770A4 (en) METHODS, KITS AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
JP2011511805A5 (https=)
FR2934156B1 (fr) Medicament appetissant a administration orale sous forme solide
IL204658A (en) Pharmaceutical preparation for topical use in the form of an opaque gel-gel containing diclofenac diethylammonium salt
BR112012003283A2 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
IL212568A (en) Annotated 4,1-Diazepan, Pharmaceutical Preparations Containing Them and Their Uses in the Preparation of Medicines for the Treatment of Diseases or Disorders of Mammals
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
DE602008004217D1 (de) Pharmazeutische zusammensetzung
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
JP2007536277A5 (https=)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
IL210204A (en) Ligand, method for preparing it, antibody and pharmaceutical composition comprising same and use thereof in the manufacture of a medicament for treating msrv-associated disease
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.